Inozyme Pharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
10-K: Inozyme Pharma Prioritizes ENPP1 Deficiency Program, Postpones Other Trials in 2024 10-K Filing
Inozyme Pharma's 2024 10-K filing highlights a strategic shift towards prioritizing its ENPP1 Deficiency program while postponing trials for ABCC6 Deficiency and calciphylaxis.
Inozyme Pharma's 2023 annual report highlights progress in clinical trials for INZ-701 and provides a financial update.